“…This study is a continuation of our research work in the design and preparation of the nitrogen‐containing heterocyclic compound ‘Indolizine’ as an anti‐TB agent. Indolizines are prime focussed due to their interest in synthetic chemistry (Lakshmikanth et al., 2023; Sandeep et al., 2013a, 2014; Sumanth et al., 2023; Venugopala et al., 2018) with medicinal applications like tuberculosis (Khedr et al., 2018; Sandeep Chandrashekharappa et al., 2019; Venugopala, Chandrashekharappa, Pillay, et al., 2019; Venugopala, Tratrat, Chandrashekharappa, et al., 2019; Venugopala, Tratrat, Pillay, et al., 2019), antioxidant (Vijayakumar Uppar, 2020), anticancer (Sandeep, Padmashali, et al., 2016), anti‐microbial (Sandeep et al., 2013b; Uppar et al., 2021; Vijayakumar Uppar, 2020), anti‐inflammatory (Chandrashekharappa, Venugopala, Tratrat, et al., 2018; Sandeep et al., 2017; Venugopala, Al‐Attraqchi, Tratrat, et al., 2019; Venugopala, Chandrashekharappa, Tratrat, et al., 2021), larvicidal (Chandrashekharappa, Venugopala, Nayak, et al., 2018; Sandeep, Venugopala, et al., 2016; Uppar et al., 2020) and NmeNANAS inhibitor (Alwassil et al., 2019). In this work, we have designed, characterized and evaluated a series of morpholine‐containing indolizine derivatives (5a‐o) (Table 1) for their anti‐tubercular potential.…”